Role of forskolin in blood-brain barrier damage in rats after cerebral injury
10.3760/cma.j.issn.1671-8925.2011.03.004
- VernacularTitle:毛喉素在大鼠脑损伤后血脑屏障损害中的作用
- Author:
Liang-Ping LI
1
;
Fang-Yi YU
;
Jia-Xiang CHEN
;
Zhi-Lei XU
;
Ru-Xiang XU
Author Information
1. 广州市红十字会医院
- Keywords:
Craniocerebral injury;
Blood-brain barrier;
Forskolin
- From:
Chinese Journal of Neuromedicine
2011;10(3):232-234
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the role of forskolin, a reagent elevating the cellular content of cAMP, in blood-brain barrier (BBB) damage in rats after cerebral injury damage. Methods Sixty male SD rats were equally randomized into normal control group, sham-operated group, injured group and forskolin treatment group. Rat models of cerebral injury in the later 2 groups were induced by the improved device of Feeney weight-dropping. Foskolin treatment group was peritoneally administered forskolin 5 mg/kg 0.5 h after the brain injury. Twenty g/L Evens blue was given through intravenous injection 23 h after the injury; all the rats were sacrificed 24 h after the injury. The permeation of Evens blue was observed qualitatively with a fluorescence microscope and measured quantitatively with a spectrophotometer. Results No obvious permeation of Evens blue was noted in the surrounding areas of the damaged tissue of normal controls and sham-operated group; Evans blue significantly permeated in the injured group; as compared with that in the injured group, the permeation of Evens blue was significantly decreased in the forskolin treatment group (P＜0.05). The level of Evens blue in the cortex and hippocampus of both side of the brain in the injured group was significantly higher that that in the normal controls and sham-operated group (P＜0.05); the level of Evens blue in the cortex of the left side of the brain in the forskolin treatment group was significantly lower that that in the injured group, but obviously higher than that in the normal controls and sham-operated group (P＜0.05).Conclusion Forskolin, the reagent elevating the cellular content of cAMP, can significantly prevent BBB opening.
